Cargando…

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes

Type 2 diabetes is associated with decreased incretin hormone response to an oral glucose load, and a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secretion. Incretin-based therapies offer a new option for treatment of type 2 diabetes. Saxagliptin, a potent, selective dipeptid...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sharma, Morali D
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878957/ https://www.ncbi.nlm.nih.gov/pubmed/20526441

Ejemplares similares

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
por: Konya, Hiroyuki, et al.
Publicado: (2014)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2011)

Antioxidant therapy as monotherapy or as an adjunct to treatment of periodontal diseases
por: Mathur, Aditi, et al.
Publicado: (2013)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
por: Ryan, Gina, et al.
Publicado: (2009)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016)

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
por: Balkau, Beverley, et al.
Publicado: (2017)

Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
por: Toth, Peter P
Publicado: (2014)

Tolerability of Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes: Results from 6 Phase III Studies
por: Davidson, Jaime A.
Publicado: (2014)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
por: Odegard, Peggy Soule, et al.
Publicado: (2009)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Men, Peng, et al.
Publicado: (2018)

Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study
por: Kajikawa, Masato, et al.
Publicado: (2019)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
por: Saine, M Elle, et al.
Publicado: (2015)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

A review of exenatide as adjunctive therapy in patients with type 2 diabetes
por: Robles, Gisela I, et al.
Publicado: (2009)

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dsdc0fduo4i4p697be7219t791